The European Medicines Agency (EMA) has issued recommendations restricting the use of calcitonin because of evidence suggesting an increased risk of cancer associated with its longterm administration. Health Canada is aware of these recommendations and is informing consumers and health professionals that it is currently assessing appropriate action for Canadians. Calcitonin is available as a nasal spray used in the treatment of osteoporosis in postmenopausal women. It is also available in an injectable form used to treat Paget's disease and severe hypercalcemia. The recommendations from the EMA include: 1) Calcitonin nasal spray to no longer be prescribed for the treatment of osteoporosis; 2) Calcitonin injectable to be used in patients with Paget's disease only when other treatments have not worked or are not appropriate, with treatment duration limited to 3 months; 3) Calcitonin injectable to be used only for hypercalcemia secondary to cancer. Health Canada will communicate any resulting new safety information to Canadians once its review is completed. To date, there have been no reports of cancer associated with calcitonin use submitted to Health Canada. Advise patients to contact their health care professionals should they require more information on calcitonin.
Sanofi Pasteur and Health Canada inform health care professionals that the distribution for ImmuCyst (Bacillus Calmette-Guerin [BCG] sub-strain Connaught) has been halted. Environmental monitoring of the production facility showed increasing levels of microorganisms, including mould, and one of the required release tests that confi rms the sterility of the product failed to demonstrate an acceptable ability to detect mould and yeast. Sanofi Pasteur is currently renovating the facility, during which time the production of BCG has temporarily been suspended. Thus far, there is no evidence of contamination in released lots and there have been no infections that might be caused by contamination reported in postmarketing surveillance. The company estimates that supplies of ImmuCyst will resume in late 2013.
AstraZeneca Canada Inc. and Health Canada inform consumers and health care professionals of a small number of product complaints received related specifi cally to the delivery device of the Pulmicort Turbuhaler, budesonide 200 mcg per metered dose, a multidose, dry powder inhaler. Pulmicort Turbuhaler is used in the treatment of bronchial asthma in patients who require inhaled steroids and in patients for whom a reduction of systemic glucocorticoids is desirable. The product complaints are related to the delivery device not working properly resulting in a failure to dispense the intended dose of the medication. Advise patients that if they do not hear the "click" sound when the "turn grip" is rotated, the device is not working properly, and the intended dose will not be inhaled, resulting in the patient not receiving their medication at the prescribed dose. Pharmacists should reinforce proper inhaler technique with patients using Pulmicort Turbuhaler and advise patients to contact their health care professionals if they have any questions or concerns. AstraZeneca's medical information line is also available for further information at 1-800-668-6000 (English) or 1-800-461-3787 (French).
GlaxoSmithKline Inc. and Health Canada inform consumers and health care professionals that Volibris (ambrisentan) is contraindicated for use in patients with idiopathic pulmonary fi brosis with or without pulmonary hypertension. Volibris is approved for use to treat idiopathic pulmonary arterial hypertension and pulmonary arterial hypertension associated with connective tissue disease. A clinical trial (ARTEMIS-IPF) looking at patients with idiopathic pulmonary fi brosis treated with Volibris was prematurely discontinued due to lack of effi cacy. In addition, the results of the trial revealed a higher rate of the composite primary endpoint, disease progression or death in patients in the Volibris arm relative to placebo. A further evaluation of the primary endpoint components revealed a higher rate of respiratory hospitalizations, mortality events and decreases in respiratory function in the Volibris arm versus placebo. The product monograph has been updated with this new information.
Caldolor (ibuprofen solution for injection by Alveda) is available as 100 mg/ mL solution for injection in 4 mL and 8 mL single dose vials. It is approved for the reduction of fever in adult patients where nonparenteral antipyretic medication is inappropriate or impossible and also for the management of moderate to severe pain as an adjunct to intravenous opioid analgesics. Given as an intravenous infusion, Caldolor should not be given as an intravenous bolus or an intramuscular injection. Ibuprofen is also available in oral dosage forms and suspensions. 
